Resultados del uso expandido del PCA3 score en una población española con sospecha de cáncer de próstata

Schroder, 2009, Screening and prostate-cancer mortality in a randomized European study, N Engl J Med, 360, 1320, 10.1056/NEJMoa0810084 Andriole, 2009, Mortality results from a randomized prostate-cancer screening trial, N Engl J Med, 360, 1310, 10.1056/NEJMoa0810696 Hugosson, 2010, Mortality results from the Goteborg randomised population-based prostate-cancer screening trial, Lancet Oncol, 11, 725, 10.1016/S1470-2045(10)70146-7 Draisma, 2003, Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer, J Natl Cancer Inst, 95, 868, 10.1093/jnci/95.12.868 Thompson, 2004, Prevalence of prostate cancer among men with a prostate-specific antigen level < or=4.0 ng per milliliter, N Engl J Med, 350, 2239, 10.1056/NEJMoa031918 Postma, 2005, Screening for prostate cancer, Eur J Cancer, 41, 825, 10.1016/j.ejca.2004.12.029 Bussemakers, 1999, DD3: a new prostate-specific gene, highly overexpressed in prostate cancer, Cancer Res, 59, 5975 Ruiz-Aragón, 2010, Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis, Actas Urol Esp, 34, 346, 10.1016/j.acuro.2010.02.019 Wang, 2009, Rational approach to implementation of prostate cancer antigen 3 into clinical care, Cancer, 115, 3879, 10.1002/cncr.24447 Marks, 2007, PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy, Urology, 69, 532, 10.1016/j.urology.2006.12.014 Haese, 2008, Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy, Eur Urol, 54, 1081, 10.1016/j.eururo.2008.06.071 Sokoll, 2008, A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy, Clin Chim Acta, 389, 1, 10.1016/j.cca.2007.11.003 Deras, 2008, PCA3: a molecular urine assay for predicting prostate biopsy outcome, J Urol, 179, 1587, 10.1016/j.juro.2007.11.038 Aubin, 2010, PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial, J Urol, 184, 1947, 10.1016/j.juro.2010.06.098 Ploussard, 2010, The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?, BJU Int, 106, 1143, 10.1111/j.1464-410X.2010.09286.x Shappell, 2009, PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting, Urology, 73, 363, 10.1016/j.urology.2008.08.459 Chun, 2009, Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram, Eur Urol, 56, 659, 10.1016/j.eururo.2009.03.029 Hessels, 2010, Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer, Prostate, 70, 10, 10.1002/pros.21032 Nakanishi, 2008, PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance, J Urol, 179, 1804, 10.1016/j.juro.2008.01.013 Auprich, 2011, Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging, Eur Urol, 59, 96, 10.1016/j.eururo.2010.10.024 Vlaeminck-Guillem, 2011, Urinary PCA3 Score Predicts Prostate Cancer Multifocality, J Urol, 185, 1234, 10.1016/j.juro.2010.11.072 Ploussard, 2011, Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance, Eur Urol, 59, 422, 10.1016/j.eururo.2010.11.044 Nyberg, 2010, PCA3 as a diagnostic marker for prostate cancer: a validation study on a Swedish patient population, Scand J Urol Nephrol, 44, 378, 10.3109/00365599.2010.521187 Schilling, 2010, Interpretation of the prostate cancer gene 3 in reference to the individual clinical background: implications for daily practice, Urol Int, 85, 159, 10.1159/000314078 Perdona, 2011, Prostate Cancer Detection in the “Grey Area” of Prostate-Specific Antigen Below 10 ng/ml: Head-to-Head Comparison of the Updated PCPT Calculator and Chun's Nomogram, Two Risk Estimators Incorporating Prostate Cancer Antigen 3, Eur Urol, 59, 81, 10.1016/j.eururo.2010.09.036 Laxman, 2008, A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer, Cancer Res, 68, 645, 10.1158/0008-5472.CAN-07-3224 Rigau, 2010, PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine, Prostate, 70, 1760, 10.1002/pros.21211 Hessels, 2007, Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer, Clin Cancer Res, 13, 5103, 10.1158/1078-0432.CCR-07-0700 Rubio-Briones, 2010, Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy, J Urol, 183, 2054, 10.1016/j.juro.2009.12.096 Roobol, 2010, Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test, Eur Urol, 58, 475, 10.1016/j.eururo.2010.06.039